Bookmark Icon
Print Icon
Email Icon
Mark L. Heaney, <span>MD, PhD</span>

Mark L. Heaney, MD, PhD

Medical Oncology (Board Certified, Primary Specialty)
Hematology (Board Certified, Primary Specialty)
Myelodysplastic Syndrome
Cancer Care
One of America's Top Doctors
Rated one of New York Magazine's Best Doctors


Mark Heaney received his undergraduate education at Harvard and graduate education at the University of Virginia where he received an M.D. and a Ph.D. in microbiology. After Internal Medicine residency at SUNY Stony Brook, he had fellowship training in Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Heaney subsequently joined the faculty at Memorial Sloan-Kettering Cancer Center. As a member of the Leukemia Service for nearly 20 years, Dr. Heaney continued laboratory research, initially studying the cell surface receptors that govern white blood cell development and leukemia cell growth. More recently, he has focused on metabolic differences between leukemia cells and normal cells that can provide insight into how leukemias behave in the individual patient and how they respond to treatment. His finding that vitamin C has the potential to blunt the beneficial effects of chemotherapy has been widely cited.

Dr. Heaney has also been an active clinical investigator. He has been the Principal Investigator of many clinical trials that have aimed at developing new treatments for leukemia. In particular, he has focused on new treatments of the myeloproliferative neoplasms, primary myelofibrosis, polycythemia vera and essential thrombocythemia, but has also studied new treatments for chronic myeloid leukemia, mastocytosis and Langerhans cell histiocytosis in keeping with his clinical expertise in rare blood cancers.

Dr. Heaney joined the faculty at CUMC in January, 2013. He has continued his commitment to caring for patients with blood cancers, developing new treatments including cutting edge clinical trials, and laboratory research that concentrates on translating discoveries from the bench to the bedside. He also renewed his investment in medical education, becoming Director of the Hematology and Medical Oncology Fellowship Program in 2014.

Area of Expertise

Please contact the doctor's office to verify that your insurance is accepted.


University of Virginia School of Medicine

MD, University of Virginia School of Medicine

Residency: Stonybrook University Hospital

Fellowship: Memorial Sloan-Kettering Cancer Center


Selected Bibliography (of more than 50):

  • Heaney ML, Vera JC, Raines MA, Golde DW:  Membrane-associated and soluble granulocyte/macrophage-colony-stimulating factor receptor a subunits are independently regulated in HL-60 cells.  Proc Natl Acad Sci USA 92:2365-2369, 1995
  • Heaney ML, Golde DW:  Myelodysplasia.  New Engl J Med 340:1649-1659, 1999
  • Niu L, Golde DW, Vera JC, Heaney ML:  Kinetic resolution of two mechanisms for high-affinity granulocyte-macrophage colony-stimulating factor binding to its receptor.  Blood  94:3748-3753, 1999
  • Golde DW, Caggiano J, Heaney ML: Cladribine misdosing in hairy cell leukemia: a cause for apparent response failure.  Leukemia Lymphoma 43: 365-367, 2002
  • Brown WE, Coakley FV, Heaney ML: CT of renal involvement by Rosai Dorfman Disease.  Abdominal Imaging 27: 214-216, 2002
  • O’Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173, 2006
  • Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O’Connor OA.  Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111:5350-8, 2008
  • Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, O’Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 68:8031-8. 2008
  • Koppikar K, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 115:2919-27, 2010
  • Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 36:500-4, 201
  • Heaney ML. Inside Blood: Saving orphans: BRAF targeting of histiocytosis. Blood 121:1487-88, 2013
  • Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA. A self-assembling short oligonucleotide duplex suitable for pretargeting. Nucleic Acid Ther 23: 289-99, 2013
  • Soriano G, Heaney M.  Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin  Hematol 20:169-75, 2013
  • Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis 5:e1152, 2014
  • Lau N, Heaney ML (Review) Evaluation of Response to First-Line Treatment for Chronic Myeloid Leukemia: Has Imatinib Been Outperformed? Int J Hematologic Oncol 3:153-168, 2014
  • Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, Ferrarini M, Abdel-Wahab O, Heaney ML, Scheel PJ, Feeley NK, Ferrero E, McClain KL, Vaglio A, Colby T, Arnaud L, Haroche J. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124:483-92, 2014
  • Heaney ML. (Review) Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest. Clin Adv Hematol Oncol 12:502-8, 2014
  • Heaney ML. (Editorial) Zeroing in on cereblon. Eur J Haematol 2015 (epub ahead of print)

Herbert Irving Pavilion

161 Fort Washington Avenue Garden Level
New York, NY 10032

Fax: (212) 305-8112

Get Directions

Associate Professor of Medicine at CUMC

  • 2014                              Fellow, American College of Physicians
  • 2008                              Abstract Reviewer and Oral Session Chair, ASH Annual Meeting
  • 2002                              Meet the Professor, ACP-ASIM Annual Meeting
  • 2001                              Hematology Fellows Attending Teaching Award, Memorial Sloan-Kettering
  • 1999                              Who’s Who In America
  • 1998-2001                  Translational Research Award, Leukemia and Lymphoma Society
  • 1996-2001                  Catherine and Frederick R. Adler Chair for Junior Faculty
  • 1993-1996                  NIH Physician Scientist Award
  • 1992                              Sloan-Kettering Clinical Scholar, Charles A. Dana Fellow
  • 1990                              American Cancer Society Clinical Fellow

Transit Advisory Notice

Starting Jan. 5, 2019, 1 trains will bypass the 168th Street subway station at NewYork-Presbyterian/Columbia University Irving Medical Center until early 2020.